コンパニオン診断(CDx)の世界市場予測2016-2026...市場調査レポートについてご紹介

【英文タイトル】The Companion Diagnostics (CDx) Market Forecast 2016-2026

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Report Overview
1.1 The Companion Diagnostics Market Overview
1.2 Companion Diagnostics Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain

2. Introduction to Companion Diagnostics
2.1 The Foundation of Personalised Medicine
2.2 Personalised Medicine: Changing the Patient Treatment Paradigm
2.3 In Vitro Diagnostic (IVD) Tests
2.3.1 Companion Diagnostics: A Type of IVD
2.3.2 Differences between Companion Diagnostics and Theranostics
2.3.3 Biomarkers to Companion Diagnostics
2.3.4 Genomic Biomarkers
2.3.5 Genomic Oncology Biomarkers
2.4 Regulations in the Companion Diagnostics Market
2.4.1 FDA’s Final Guidance on Companion Diagnostics
2.4.2 LDTs: A Changing Landscape
2.5 Encouraging the Contemporaneous Development of Companion Diagnostics

3. The World Companion Diagnostics Market, 2016-2026
3.1 Scope and Limitations
3.2 The Global Companion Diagnostics Market, 2014 and 2015
3.3 The Global Companion Diagnostics Market Sales Forecast, 2016-2026
3.4 Companion Diagnostics: Growth Outpacing the Rest of the IVD Market
3.5 Companion Diagnostics: Increasing Market Share of the IVD Market
3.6 The Companion Diagnostics Market by Submarket, 2014
3.7 Theranostics: Fastest Growing Segment of the CDx Market
3.8 Changing Market Shares of the Leading Companion Diagnostics Submarkets, 2015-2025

4. Leading National Markets for Companion Diagnostics, 2016-2026
4.1 The Leading National Markets for Companion Diagnostics: Led by 3 Dominant Markets in 2014 & 2015
4.2 The Leading National Markets for Companion Diagnostics Sales Forecast, 2016-2026
4.2.1 Changing Market Shares of Leading National Markets, 2016-2026
4.3 The US Companion Diagnostics Market Sales Forecast, 2016-2026
4.3.1 The US Will Continue to Dominate the Market
4.4 The EU5 Companion Diagnostics Sales Market, 2014
4.4.1 The EU5 Companion Diagnostics Market Sales Forecast, 2016-2026
4.4.2 Changing Market Shares of the EU5 Companion Diagnostics Market
4.4.3 The German Companion Diagnostics Market Sales Forecast, 2016-2026
4.4.4 The French Companion Diagnostics Market Sales Forecast, 2016-2026
4.4.5 The Italian Companion Diagnostics Market Sales Forecast, 2016-2026
4.4.6 The Spanish Companion Diagnostics Market Sales Forecast, 2016-2026
4.4.7 The UK Companion Diagnostics Market Sales Forecast, 2016-2026
4.5 The Japanese Companion Diagnostics Market Sales Forecast, 2016-2026
4.5.1 Japan’s Medical Technology Regulatory Process Reducing Time to Market
4.6 The Chinese Companion Diagnostics Market Sales Forecast, 2016-2026
4.6.1 Cancer Rates will Drive Adoption of Companion Diagnostic Tests
4.7 The Indian Companion Diagnostics Market Sales Forecast, 2016-2026
4.8 The Brazilian Companion Diagnostics Market Sales Forecast, 2016-2026
4.9 The Russian Companion Diagnostics Market Sales Forecast, 2016-2026
4.10 The South Korean Companion Diagnostics Market Sales Forecast, 2016-2026
4.11 The Rest of the World Companion Diagnostics Market Sales Forecast, 2016-2026

5. The Companion Diagnostics Market: Marketed Products and Pipeline Partnerships
5.1 Biomarkers: At the Forefront of Companion Diagnostics Development
5.2 US FDA Approved Companion Diagnostic Tests, 2016
5.3 Oncology Continues to Dominate the R&D Pipeline of Companion Diagnostics
5.4 Expensive Cancer Therapies Encourages the Development of CDx
5.5 Companion Diagnostic/Pharma Partnerships, 2013-2014

6. Business Models and Stakeholders in the Companion Diagnostics Market
6.1 Business Models for the Development of Companion Diagnostics
6.1.1 The Partnership Model is the Most Practiced Method
6.1.2 The Stand-Alone Model: Licensing an IP
6.1.3 The One Stop Shop Model: An Approach by Big Pharma
6.1.4 Using Contract Diagnostics Organisations (CDO): An Emerging Trend
6.2 Factors Driving Companies to Enter the Companion Diagnostics Market
6.3 Stakeholders Influencing the Companion Diagnostics Market
6.3.1 Pharmaceutical Companies and Diagnostic Manufacturers
6.3.2 Regulatory Authorities
6.3.3 Testing Laboratories
6.3.4 Physicians and Patients
6.3.5 Payers
6.4 Companion Diagnostics Competitive Landscape, 2016

7. Leading Companies in the Companion Diagnostics Market 2015
7.1 Roche: Global Diagnostics Leader
7.1.1 Ventana Medical Systems (Roche)
7.1.2 Sales and Recent Performance Analysis, 2014
7.1.3 Roche Diagnostics by Region, 2014
7.1.4 Roche: Internal Growth
7.1.5 Approval of Tarceva and Cobas EGFR Mutation Test
7.1.6 Roche’s Portfolio of Companion Diagnostic Project Pipeline and Marketed Companion Diagnostics, 2015
7.1.7 Ventana Companion Diagnostics: Robust New Prototype Assays
7.1.8 Recent Companion Diagnostic External Collaborations, 2014-2015
7.1.8.1 Ventana/Genmab
7.1.8.2 Ferring/ Roche: CDx Development for Infertility Treatment
7.1.8.3 MedImmune (AstraZeneca)/Ventana: Assay for NSCLC Targeted Clinical Trials
7.1.8.4 Merck/Ventana: CDx for an Undisclosed Target
7.1.8.5 AstraZeneca/Roche: CDx to Support Target Drug AZD9291
7.1.8.6 Boehringer Ingelheim/Roche
7.1.8.7 ImmunoGen/ Ventana
7.1.8.8 Foundation Medicine/Roche
7.1.9 Roche: Major M&A Activity and Strategic Partnerships Strengthen Position as Diagnostic Market Leader
7.1.9.1 Genia Acquisition to Strengthen DNA Sequencing Capabilities
7.1.9.2 IQuum Acquisition Allows Movement into POC MDx Market
7.1.9.3 Seragon Acquisition Strengthens Leading Position in Oncology
7.1.9.4 Santaris Acquisition Enchances Roche’s Position in RNA-Targeted Drugs Market
7.1.9.5 Bina Acquisition Brings Big Data Solution to Support NGS Development
7.1.9.6 Dutalys Acquisition Enhances Roche’s mAB Portfolio
7.1.9.7 Ariosa Acquisition Adds NIPT to Diagnostic Portfolio
7.1.9.8 Foundation Medicine Deal Enhances Personalised Medicine Capabilities for Oncology
7.1.9.9 Signature and CAPP Acquisitions Strengthen Circulating DNA Testing Abilities
7.1.9.10 GENEWEAVE and Kapa Acquisitions Help Cement Roche’s Position as the Market Leader
7.2 Qiagen N.V.: Leading CDx Collaborator with Pharmaceutical Companies
7.2.1 Sales and Recent Performance Analysis, 2010-2015
7.2.2 Qiagen Sales By Region
7.2.3 Companion Diagnostics Collaboration Agreements with Pharma, 2015
7.2.3.1 Collaboration with Eli Lilly
7.2.3.2 Collaboration with AstraZeneca
7.2.3.3 Collaboration with Astellas Pharma
7.2.3.4 Collaboration with Novartis
7.2.3.5 Collaboration with Array BioPharma
7.2.3.6 Collaboration with Protagen
7.3 Abbott Molecular: An Established Competitor
7.3.1 Sales and Recent Performance Analysis, 2012-2015
7.3.2 Abbott Molecular: Expansive Oncology Biomarker Pipeline
7.3.3 Recent Activity and Collaborations
7.3.3.1 Collaboration with Merck
7.3.3.2 Collaborative Efforts with Idera
7.3.3.3 Collaboration with AstraZeneca
7.4 Agilent Technologies (Dako)
7.4.1 Life Sciences and Diagnostics Business
7.4.2 Agilent Life Sciences and Diagnostics, Sales and Recent Performance Analysis, 2015
7.4.3 Agilent: Next Generation Sequencing Platforms
7.4.4 Recent Companion Diagnostic Collaborations
7.4.4.1 Agilent/ Merck: Several Cancer Collaborations
7.4.4.2 Agilent/Pfizer: An Ongoing Collaboration
7.4.4.3 Agilent/Bristol-Myers Squibb
7.5 Myriad Genetics
7.5.1 Acquisition of Myriad RBM: Increases the Company’s Market Share of Companion Diagnostics
7.5.2 Companion Diagnostic Service Offerings
7.5.3 Sales and Recent Performance Analysis, 2013-2014
7.5.3.1 myRisk: Next Generation Hereditary Cancer Testing
7.5.4 Myriad Genetics Recent Collaborations
7.5.4.1 Myriad/AstraZeneca: Premarket Approval Application
7.5.4.2 Acquisition of Crescendo Bioscience: Entry into the Autoimmune Market
7.5.4.3 Myriad/ TESARO Companion Collaboration
7.5.4.4 Collaboration with AbbVie
7.6 BioMérieux
7.6.1 Sales and Recent Performance Analysis, 2010-2015
7.6.2 Sales by Region, 2014
7.6.3 Sales by Technology, 2015
7.6.4 Companion Diagnostics: Recent M&A Activity & Collaboration
7.6.4.1 Collaboration with Gilead Sciences
7.6.4.2 Collaboration with Ipsen
7.6.4.3 Collaboration with Merck
7.6.4.4 Collaborations with GSK and Novartis
7.6.4.5 Mergers, Acquisitions and Collaborations
7.6.5 bioTheranostics: Subsidiary for Oncology Diagnostics
7.7 Thermo Fisher Scientific
7.7.1 Sales and Recent Performance Analysis, 2013-2014
7.7.1.1 Thermo Fisher Scientific Sales by Region, 2015
7.7.2 Recent Collaborations and Acquisitions
7.7.2.1 Acquisition of Life Technologies
7.7.2.2 Acquisition of Prionics
7.7.2.3 Acquisition of Advanced Scientifics, Inc.
7.7.2.4 Acquisition of Alfa Aesar
7.7.2.5 Affymetrix: Thermo Fisher’s Next Target
7.7.2.6 Thermo Fisher: Developing a ‘Universal’ Companion Diagnostics Using Next Generation Sequencing
7.7.2.7 Thermo Fisher: Life Technologies Collaborates with Merck Serono
7.7.2.8 Thermo Fisher Scientific Collaboration with Pfizer and Novartis to Offer NGS-Based Companion Test for NSCLC

8. Qualitative Analysis of the Companion Diagnostics Market, 2016-2026
8.1 SWOT Analysis of the Companion Diagnostics Market
8.2 Strengths
8.2.1 A CDx Strategy Decreases the Length of Approval Process
8.2.2 Premium Prices for Companion Diagnostics
8.2.3 A CDx Development Strategy Can Generate More Effective Drugs
8.2.4 Therapeutics Tied with CDx can have Safer Profiles
8.2.5 Reducing the Cost of Healthcare
8.2.6 Increased Regulatory Scrutiny on Marketed Drugs
8.2.7 Targeted Therapies Will Drive the CDx Market
8.3 Weaknesses
8.3.1 Reimbursement Challenges
8.3.2 Lack of Clear Regulatory Guidelines
8.3.3 Capital Intensity is High
8.4 Opportunities
8.4.1 Fast-growing Emerging Markets
8.4.2 Next Generation Sequencing
8.4.3 Many New CDx/ Pharma Company Partnerships
8.5 Threats
8.5.1 Complex Business Models and Business Partnerships
8.5.2 Medical Device Excise Tax
8.6 Porter’s Five Forces Analysis of the Companion Diagnostics Market
8.6.1 Rivalry Among Competitors [High]
8.6.2 Power of Suppliers [High]
8.6.3 Power of Buyers [Medium]
8.6.4 Threat of New Entrants [Medium]
8.6.5 Threat of Substitutes [High]

9. Conclusions
9.1 Overview
9.2 Theranostics: A Fast Growing Market
9.3 Leading Companion Diagnostic Companies
9.4 Pharmaceutical/Diagnostic Partnership Model
9.5 Oncology is the Leading Therapy Area Driving Companion Diagnostics
9.6 Commercial Drivers of the Companion Diagnostics Market
9.7 Commercial Restraints of the Companion Diagnostics Market
9.8 Concluding Remarks

10. Glossary

Appendix
Visiongain’s Bespoke Research Service
Some Associated Reports
Visiongain Report Sales Order Form
About Visiongain
Report Evaluation Form


【レポート販売概要】

■ タイトル:コンパニオン診断(CDx)の世界市場予測2016-2026
■ 英文:The Companion Diagnostics (CDx) Market Forecast 2016-2026
■ 発行日:2016年3月
■ 調査会社:visiongain
■ 商品コード:VGAIN6041538
■ 調査対象地域:グローバル
  • M-キシリレン・ジイソシアネートの世界市場
    M-Xylylene Diisocyanate (CAS 3634-83-1) Market Research Report 2013 presents comprehensive data on m-xylylene diisocyanate markets globally and regionally (Europe, Asia, North America etc.) The M-Xylylene Diisocyanate (CAS 3634-83-1) Market Research Report 2013 includes m-xylylene diisocyanate description, covers its application areas and related patterns. It overviews m-xylylene diisocyanate mark …
  • データ品質管理ツールの世界市場2015-2019
    About Data Quality Tools Data quality tools refer to the wide range of tools required for ensuring quality and reliability of data in various business processes including core business operations, BI, analytics, and decision making. The data quality vendors offer a wide range of functionalities including data profiling, monitoring, parsing, standardization, and data enrichment. These tools are app …
  • 世界の人工心血管置換装置開発動向:医療機器パイプライン分析2015
    Cardiovascular Prosthetic Devices - Medical Devices Pipeline Assessment, 2015 Summary GlobalData's Medical Devices sector report, “Cardiovascular Prosthetic Devices - Medical Devices Pipeline Assessment, 2015" provides an overview of Cardiovascular Prosthetic Devices currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the …
  • 水中ポンプの世界市場2018-2022
    122 pages, November 2018 About this market IoT devices are increasingly being adopted by key-end user industries such as oil and gas for data capture and in-depth monitoring. This have resulted in improved overall performance efficiency for submersible pumps. The moderate recovery in crude oil prices in 2017 have prompted rig operators and oil producers to focus on the improvement of energy effici …
  • 世界主要国のフィブリノーゲン検査(医療機器)市場
    The growing cost-containment pressures in major industrialized nations and continued technological advances will radically change coagulation testing practice during the next ten years. New specific and sensitive markers of hemostasis will be increasingly used on automated instrumentation. Coagulation testing in general, and Fibrinogen testing specifically, will become more standardized, offering …
  • 欧州の風力発電産業分析:Analyzing the European Wind Power Industry
    As demand on finite petroleum reserves and the price of the fuels derived from them continues to rise, renewable forms of energy are becoming more cost-effective and profitable. In the forefront of this renewable revolution is harnessing the sustainable power of wind. Today it is one of the most positive developments created by the present storm of uncertainty unleashed as a result of escalating o …
  • Market Opportunity: Mobile Phone Augmented Reality
    Augmented Reality (AR) via a mobile phone refers to augmentation of what the end-user views with the screen. This is based on overlaying data onto the screen view, which may present a view of the real-world via the camera and points of interest and/or information that is put into the view, virtually, but not really existing in the real-world. AR represents a potential large opportunity for 4G (and …
  • 世界のEPDMシールストリップ市場2015
    < Global EPDM Sealing Strip Industry Report 2015> is a professional and deep research report on Global and China EPDM Sealing Strip industry. For overview analysis, the report introduces EPDM Sealing Strip basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis, etc. For international and China market anal …
  • コードレス造園機器の世界市場2019-2023
    About this market The continuously increasing product awareness through numerous marketing campaigns will foster the cordless garden equipment market growth during the forecast period. Campaigns against noise-generating garden equipment and growing calls for quieter alternatives will augment the market growth. Several programs are also encouraging the use of clean battery-powered lawns and garden …
  • スマートシリンジポンプの世界市場2019-2023
    About this market The growing number of surgical procedures and technological advances will foster market growth during the forecast period. Due to the rising incidence of several diseases, the number of surgical procedures performed annually has increased over the last decade. Smart syringe pumps are used as an important therapeutic tool to deliver medications continuously during critical care an …
  • ITセキュリティテストの世界市場予測(~2021年):ネットワーク、アプリケーション、デバイス
    The security testing market size is expected to grow from USD 3.31 Billion in 2016 to USD 7.61 Billion by 2021, at a Compound Annual Growth Rate (CAGR) of 18.1% during the forecast period. The major growth drivers of the market include the need to protect valuable assets such as web & mobile applications and customer data and meet government mandates and regulatory compliances. The security testin …
  • Neonatal Respiratory Distress Syndrome:グローバル臨床試験レビューH2, 2013
    Neonatal Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2013 Summary GlobalData's clinical trial report, “Neonatal Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2013" provides data on the Neonatal Respiratory Distress Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neonatal Respiratory Dis …
  • 合法的傍受の世界市場2019-2023
    Technavio Announces the Publication of its Research Report – Global Lawful Interception Market 2019-2023 Technavio recognizes the following companies as the key players in the global lawful interception market: AQSACOM, Inc, Cisco, Utimaco GmbH, Verint, ZTE Corporation. Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is the growing …
  • 人工膵臓装置システム(APDS)の世界市場分析:タイプ別(閾値超過デバイスシステム、制御範囲(CTR)システム、制御-ターゲット(CTT)システム)、セグメント予測
    The global artificial pancreas device system (APDS) market is expected to reach USD 390 million by 2024, according to a new report by Grand View Research, Inc. Rising occurrence of diabetes, increasing incidence of adverse effects due to improper insulin administration, and the growing interest of industry participants in the development of innovative treatments are some vital impact rendering dri …
  • Astro-Med, Inc.:市場シェア分析
    Astro-Med, Inc. Market Share Analysis Summary GlobalData’s new report, “Astro-Med, Inc. Market Share Analysis” provides in-depth information on Astro-Med, Inc.’s market position in the different medical equipment markets it operates in. The report provides Astro-Med, Inc. market share information in two key market categories – Respiratory Measurement Devices and Sleep Apnea Diagnostic Systems. The …
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。